SCHEMBL7076384

SCHEMBL7076384

CCCn1c(C(N)=O)c(N2CCC(Cc3ccccc3)CC2)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
KDM4E B2RXH2 1/20 0.47
HTR7 P34969 4/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PRMT3 O60678 1/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT1 Q99873 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
KCNH2 Q12809 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.41
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7076394 0.82 KCNH2 (0.47) MAPTKDM4EHTR7ALDH1A1GAA
SCHEMBL5377672 0.75 HDAC6 (0.49) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL5732388 0.75 GAA (0.49) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL5277418 0.73 KDM4E (0.60) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL5733938 0.71 HDAC6 (0.42) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL7078851 0.70 MEN1 (0.52) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL5489419 0.69 NPC1 (0.46) KDM4EALDH1A1GAAMEN1KMT2A
SCHEMBL5375992 0.69 MEN1 (0.53) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL23410008 0.68 NR3C1 (0.47) MAPTKDM4EHTR7ALDH1A1NPSR1
SCHEMBL29980507 0.68 NR3C1 (0.47) MAPTKDM4EHTR7ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073699-A1 Compounds and methods to treat cardiac failure and other disorders SCIOS, INC. 2003-04-17 US disclosed
US-6130235-A PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. SCIOS INC. (US) 2000-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073699-A1 Compounds and methods to treat cardiac failure and other disorders RCOR1, NR3C2, CNR1 MAPT 3270/4885KDM4E 3236/4885HTR7 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.